Latest from MSKCC

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).
 
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses androgen receptor therapy (ADT)-associated cardiac complications in prostate cancer.
The triplet regimen of pembrolizumab (Keytruda) plus umbralisib and ublituximab reached a 90% response rate in patients with relapsed/refractory chronic lymphocytic leukemia. 
Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety signals with the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) in endometrial cancer.
Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval larotrectinib in NTRK-positive cancers.
 
Charles M. Rudin, MD, PhD, reflects on the latest developments in small cell lung cancer.
Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.
 
Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses challenges in the treatment of patients with metastatic urothelial carcinoma.
 
Publication Bottom Border
Border Publication
x